Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MREO
Strong SellSinkerMereo BioPharma Group plc · Healthcare · United Kingdom · $50M · Avg Vol: $2M/d
12
StockRankGet insider-trade alerts
Q
27
V
33
M
30
P/E (TTM)
—
ROE
-67.8%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 10.0M | 0 | 0.5M | -77.6% | — | 14.4M | 436.2% |
| EPS | -1.42 | -0.88 | -1.46 | -1.25 | — | -0.20 | — | — |
| Shares | 159.6M | 159.6M | 159.6M | 159.6M | 0.0% | 159.7M | — | — |
| Debt | 15.4M | 6.0M | 6.4M | 0.2M | -76.4% | 1.0M | — | — |
| Equity | 51.4M | 50.5M | 61.0M | 40.9M | -7.3% | — | — | — |
| Op CF | -48.8M | -21.1M | -32.8M | -31.0M | — | -25.3M | — | — |
| Inv CF | 2.0M | -0.4M | -0.7M | -20.0K | — | — | — | — |
| Fin CF | 0.2M | 8.0M | 46.1M | 0.3M | — | — | — | — |
Loading 1Y...
PRICE (1Y)-16.6%
SMA 50SMA 200
Close
$0.2559
RSI (14)
27.7
52W High
$2.37
From 52W High
0.1%
SCORE BREAKDOWN
Quality
27
ROIC
-85.6%8.4
ROE
-67.8%14.3
GP/Assets
-0.0%9.3
Op. Margin
0.0%38.1
FCF/Assets
-68.1%4.5
Piotroski
559.7
Int. Cover
-50.0x5.9
D/E Ratio
0.04x74.6
Current Ratio
5.88x76.7
Value
33
P/E (TTM)
—N/A
EV/EBITDA
-0.3x25.0
P/FCF
—N/A
P/B
1.4x76.2
P/S
—N/A
Div Yield
—N/A
Momentum
30
52W High %
11%1.2
RS 6M
-50%13.3
SMA 50/200
0.54x2.8
EPS Rev 4W
+31.2%96.6
EPS Rev 12W
—N/A
EPS Improve
+88%70.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$50M
P/E (Forward)
-10.7x
Gross Margin
73.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MREO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MREO | Mereo BioPharma Group plc(you) | $50M | 12 | Strong Sell |
| COIL.L | Coiled Therapeutics plc | $51M | 4 | Strong Sell |
| SBTX.L | SkinBioTherapeutics plc | $33M | 11 | Strong Sell |
| SAR.L | Sareum Holdings plc | $63M | 19 | Strong Sell |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | $52M | 0 | Strong Sell |
| 4BB.L | 4basebio PLC | $110M | 11 | Strong Sell |
| OKYO | OKYO Pharma Limited | $88M | 5 | Strong Sell |
| IMM.L | ImmuPharma plc | $30M | 1 | Strong Sell |
| APTA.L | Aptamer Group PLC | $25M | 3 | Strong Sell |
| POLB.L | Poolbeg Pharma PLC | $89M | 25 | Sell |
Peer medians: ROE -1.8% · P/E 24.4x · Gross margin 55.3%